Companies focus on hard science, long-term pay-off at stem cell meeting

Just because the science is hard that doesn't mean that biotechnology firms won't conduct pioneering regenerative medicine research or that major pharmaceutical companies won't invest in cell therapies. Regulatory approval for new products and health care payer reimbursement for innovative treatments also are possible despite the novelty of the field.